首页> 外文OA文献 >A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

【2h】

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

机译：对ER + / HER2-先进的乳腺癌的新口腔选择性雌激素受体降解剂AZD9496的第一次人类研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Erika P. Hamilton; Manish R. Patel; Anne C. Armstrong; Richard D. Baird; Komal Jhaveri; Matthias Hoch; Teresa Klinowska; Justin P.O. Lindemann; Shethah R. Morgan; Gaia Schiavon; Hazel M. Weir; Seock-Ah Im;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2(-) Advanced Breast Cancer [J] . Hamilton Erika P., Patel Manish R., Armstrong Anne C., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第15期

机译：对ER + / HER2（ - ）晚期乳腺癌的新口腔选择性雌激素受体降解剂AZD9496的先进研究
2. A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：第一阶段Ⅰ阶段研究，评估口服选择性雌激素受体降解剂（SERD），GDC-9545，雌激素受体阳性（ER +）HER2阴性（HER2-）转移性乳腺癌的绝经后妇女
3. EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：祖母绿：一个随机的，开放标签，第3阶段试验，以评估享受新的口服选择性雌激素受体降解剂（SERD），VS调查患者对ER + / HER2晚期乳腺癌的内分泌治疗选择的疗效和安全性 CDK4 / 6抑制剂治疗
4. Insilico docking studies of daidzeion compounds as selective estrogen receptor modulator (SERMS) breast cancer [C] . Yani Suryani, Opik Taupiqurrohman, Ai Rikani, Applied Sciences and Engineering Conference . 2018

机译：Daidzeion化合物作为选择性雌激素受体调节剂（SERMS）乳腺癌的Insilico对接研究
5. Hormonal exposures and breast cancer characterized by estrogen receptor and progesterone receptor status and Her2/neu oncogene amplification. [D] . Huang, Wen-Yi. 1998

机译：以雌激素受体和孕激素受体状态以及Her2 / neu癌基因扩增为特征的激素暴露和乳腺癌。
6. RAD1901: a novel orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models [O] . Fiona Garner, Maysoun Shomali, Dotty Paquin, -1

机译：RAD1901：一种新型的可口服生物利用的选择性雌激素受体降解剂在乳腺癌异种移植模型中显示出抗肿瘤活性
7. Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer [O] . R. Xiong, Y. Li, J. Zhao, 2019

机译：基本选择性雌激素受体降解剂（B-SERDS）与ER +乳腺癌的新型BET抑制剂组合

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅